Core Laboratories Q4 EPS of $0.21 Beats Estimate, Revenues Jump 7% to $138.3M
Core Laboratories reported Q4 adjusted EPS of $0.21, beating estimates by $0.01, on revenues of $138.3 million, up 7% year-over-year and $6.3 million above consensus. Total costs rose 6.4% to $122.4 million, while the Production Enhancement segment swung to $3.0 million operating income from a $2.6 million loss.
1. Q4 Financial Performance
Core Laboratories delivered adjusted earnings per share of $0.21 in Q4, surpassing the consensus of $0.20. Operating revenues reached $138.3 million, up 7% from $129.2 million, driven by higher demand for laboratory analytical and completion diagnostic services internationally.
2. Cost and Expense Trends
Total costs and expenses climbed 6.4% to $122.4 million, reflecting seasonally weak U.S. land activity and segment underperformance. The higher cost base narrowed operating margins despite top-line growth.
3. Segment Results
The Reservoir Description segment posted $92.3 million in revenue, up 6.3%, but saw operating income decline to $12.8 million. Production Enhancement revenues rose 8.3% to $46.0 million and generated $3.0 million in operating income versus a prior-year loss.
4. Capital Allocation and Balance Sheet
During the quarter, the company repurchased 363,207 shares for $5.7 million and reduced net debt by $1.2 million, bringing net debt to $87.5 million. Cash on hand stood at $22.8 million as of December 31, 2025, supporting dividend maintenance and debt leverage of 1.09x.